Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM26SR7)

• Drug Name: Benzyloxyresorufin Drug Info
• Synonyms: Benzyloxyresorfin; 7-Benzyloxyresorufin; J-100240; MCULE-6922850124; O7-Benzylresorufin; Resorufin benzyl ether; SCHEMBL563335; STK299141; ZINC4534147; 3H-Phenoxazin-3-one, 7-(phenylmethoxy)-; 7-(Phenylmethoxy)-3H-phenoxazin-3-one; 7-(benzyloxy)-3H-phenoxazin-3-one; 7-Benzoxyresorufin; 7-Benzyloxy-3H-phenoxazin-3-one; 87687-02-3; AKOS005429005; CTK8D9518; DTXSID90236553; FT-0642066; MFCD00171613; Resorufin benzyl ether CYP450 substrate; Resorufin benzyl ether, CYP450 substrate
• Cross-matching ID:
  PubChem CID: 114982
  CAS Number: CAS 87687-02-3
  TTD Drug ID: DM26SR7
  INTEDE Drug ID: DR2451

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[5]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[6]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[7]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[9]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[11]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[12]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[13]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[17]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[19]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[20]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[22]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[23]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[24]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[25]

Drug(s) Metabolized By Cytochrome P450 102A1 (cyp102)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[15]
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[2]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[16]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[16]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[2]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[2]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[14]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[14]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[26]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[27]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[28]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[29]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[30]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[31]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[32]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[33]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[34]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[35]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[1]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Regulation of Drug Effects	[3]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[4]

References

• [1] P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001 Mar;29(3):304-12.
• [2] The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
• [3] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [4] Structure-dependent genotoxic potencies of selected pyrrolizidine alkaloids in metabolically competent HepG2 cells. Arch Toxicol. 2020 Dec;94(12):4159-4172. doi: 10.1007/s00204-020-02895-z. Epub 2020 Sep 10.
• [5] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [6] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [7] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [8] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [9] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [10] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [11] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [12] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [13] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [14] Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
• [15] acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
• [16] Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
• [17] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [18] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [19] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [20] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [21] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [22] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [23] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [24] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [25] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [26] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [27] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [28] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [29] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [30] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [31] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [32] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [33] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [34] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [35] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.